Arkolith/Insider Trading/CADL/Form 4

Tak Paul Peter

Chief Executive Officer, DirectorCandel Therapeutics, Inc. (CADL) · full profile →Form 4 · filed Mar 20, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$230K
Net Open-Market Flow
-$230K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 19, 2025Sell(S)400$9.00$4K226K
Mar 18, 2025Sell(S)26K$8.77$226K226K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-042725) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML